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Abstract
Purpose PERFORM is exploring the efficacy of terutroban
versus aspirin for secondary prevention in patients with a
history of ischemic stroke or transient ischemic attacks
(TIAs). The PERFORM Vascular Project will evaluate the
effect of terutroban on progression of atherosclerosis, as
assessed by change in carotid intima-media thickness
(CIMT) in a subgroup of patients.
Methods and results The Vascular Project includes struc-
tural (CIMT, carotid plaques) and functional (carotid
stiffness) vascular studies in all patients showing at least
one carotid plaque at entry. Expected mean follow-up is
36 months. Primary endpoint is rate of change of CIMT.
Secondary endpoints include emergent plaques and assess-
ment of carotid stiffness. 1,100 patients are required for
90% statistical power to detect treatment-related CIMT
difference of 0.025 mm. The first patient was randomized
in April 2006.
Conclusions The PERFORM Vascular Project will investi-
gate terutroban’s effect on vascular structure and function in
patients with a history of ischemic stroke or TIAs.
Key words Antiatherosclerotic activity.Antiplatelet
agent.Atherosclerosis.Carotid intima-media thickness.
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Introduction
Terutroban is a specific thromboxane prostaglandin (TP)
receptor antagonist [1]. It is an antiplatelet agent, at least as
effective as aspirin [2] with potential additional antiathero-
sclerotic and antivasoconstrictive properties. It is expected to
be useful in the secondary prevention of cerebrovascular and
cardiovascular events in patients with a history of ischemic
stroke and recent transient ischemic attacks (TIAs). This is
currently being evaluated in a large-scale ongoing phase III
randomized controlled trial, PERFORM (Prevention of
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DOI 10.1007/s10557-010-6231-2cerebrovascular and cardiovascular Events of ischemic
origin with teRutroban in patients with a history oF ischemic
strOke or tRansient ischeMic attack). The PERFORM study
includes 19,119 patients, who are randomly allocated to
treatment with either terutroban 30 mg/day or aspirin
100 mg/day, and will be followed up for at least 3 years.
The rationale and design of the PERFORM study have been
described elsewhere, as well as the characteristics of the
whole population at baseline [3, 4].
PERFORM is powered to detect the superiority of
treatment with terutroban versus aspirin for prevention
of the primary endpoint, which is a composite of fatal
and nonfatal ischemic stroke, fatal and nonfatal myo-
cardial infarction, or other vascular death. Here we
describe the rationale and design of an ancillary study
of PERFORM, the PERFORM Vascular Project, which
has been specifically designed to study the effect of
terutroban on the progression of atherosclerosis, as
assessed by carotid intima-media thickness (CIMT),
carotid plaques, and carotid stiffness in a subgroup of
PERFORM participants.
Rationale
TP receptors are deeply involved in the atherosclerotic
process whether they are located on platelets, immune cells
(monocytes/macrophages or lymphocytes), or vascular cells
(smooth muscle cells, endothelial cells). Indeed, injury-
induced vascular proliferation is reduced in mice that are
genetically deficient in TP receptors. In contrast, this
response is increased in mice that have been genetically
modified and overexpress TP receptors (TPOE mice), but
blocked when TPOE mice are treated with terutroban [5].
Inhibition of the TP receptors with an agent such as
terutroban can therefore be expected to have a broad action
on atherosclerosis. This had been shown for the first time in
APOE deficient mice, in which terutroban, in contrast to
aspirin, decreased atherosclerotic plaque formation most
likely related to its anti-adhesive properties [6]. The anti-
atherosclerotic activity of terutroban has further been
investigated in several animal models. In apobec-1/LDL
receptor double knockout mice, terutroban delayed athero-
genesis at the arch of the aorta compared with placebo and
compared with a specific COX1/COX2 inhibition by
indomethacin [7]. In cholesterol-fed New Zealand rabbits,
an established animal model for advanced atherosclerosis,
terutroban induced a regression of atherosclerotic plaque, as
well as a significant reduction in the markers for macro-
phages, apoptotic cells, metalloproteinases, and endothelin-
1, and a relative increase in vascular smooth muscle cells,
suggesting that terutroban not only halts the progression of
atherosclerosis, but also transforms lesions towards a more
stable phenotype [8]. These results are in line with those
from another animal studies, in which terutroban was found
to enhance atherosclerotic lesion stability [9].
As regards terutroban’s effects on vasoreactivity and
endothelial function, this has been evaluated in atheroscle-
rotic patients with endothelial dysfunction receiving
treatment with aspirin. Terutroban improved endothelium-
dependent dilatation evaluated on the forearm versus
placebo. These results strongly support beneficial vascular
effects of terutroban through a platelet-independent mech-
anism in patients already treated with aspirin [10].
Atherosclerosis is a dynamic and progressive inflamma-
tory disease that precedes clinical vascular events such as
myocardial infarction and ischemic stroke, and can be
assessed non-invasively in a valid and reproducible manner
with carotid ultrasound. In clinical trials, Carotid Intima-
Media Thickness (CIMT) is used as a surrogate endpoint
for atherosclerosis. The association between CIMT and
cardiovascular risk factors has been demonstrated, and
CIMT, as measured by B-mode ultrasonography, has been
found to be a powerful predictor of cardiovascular and
cerebrovascular outcomes [11–15]. This non-invasive tech-
nique allows sequential follow-up measurements in epide-
miological and clinical trials with the best precision when
using standardized methods [16]. Moreover, vascular
ultrasound can also be used to assess atherosclerotic
changes in the arterial wall expressed by the occurrence
of carotid plaque [17] and by local arterial stiffness. In the
PERFORM Vascular Project, CIMT will be evaluated over
3 years to allow for sufficient time to detect antiprolifer-
ative and antiatherogenic activity. This is in line with the
study duration of other trials that investigated the effects of
various agents on CIMT [18–21].
Design
The PERFORM Vascular Project is an ancillary study of
the randomized, double-blind, controlled, parallel-group,
phase III PERFORM study, which is ongoing in 802
centers in 46 countries [3, 4]. Of these, 52 centers in 16
countries have agreed to participate in the Vascular
Project.
The main PERFORM study included patients aged
≥55 years, who had a cerebral or retinal infarction in the
last 3 months preceding inclusion or TIA in the last 8 days,
and who were stable at inclusion with no intracranial
hemorrhage or non-ischemic neurological disease. The
inclusion criteria for the PERFORM Vascular Project were
men or women participating in the main study aged between
55 and 80 years, with validated baseline (M0) vascular
evaluation including (1) an assessment of the quality of the
images (positioning, recording); (2) confirmation that both
176 Cardiovasc Drugs Ther (2010) 24:175–180common carotid arteries (CCA) were visible and at least one
carotid plaque was present; and (3) at least one CIMT
measurement on a CCA segment free of plaque was
possible. Patients were excluded from the Vascular Project
because of absence of carotid plaque, carotid stenosis ≥70%
or complete carotid obstruction (CCA, internal carotid artery
[ICA], or bifurcation), or a history of carotid surgery,
including percutaneous intervention (stent placement).
The trial profile of the PERFORM Vascular Project is
shown in Fig. 1. The first (baseline) ultrasonographic
assessment of vascular function (CIMT) is performed at
randomization (i.e., the M0 visit) prior to treatment
allocation. Ultrasonographic vascular explorations will then
be performed within 15 days of the M12 (12 months after
baseline), M24, M36 (if applicable) visits, and then at the
final visit, according to a prespecified procedure.
Participants in the Vascular Project were fully informed
and written consent was obtained according to local
regulatory requirements.
Assessments
Collection of ultrasound data and subsequent analysis of the
ultrasound images is being carried out in close agreement
with the Mannheim Carotid Intima-Media Thickness
Consensus [16].
Ultrasonographic acquisition
B-mode scanning is being performed by sonographers
trained and certified specifically for the PERFORM
Vascular Project. CIMT measurements are made using B-
mode duplex ultrasound scanner (linear array ≥7 MHz, or
broadband 5–10 MHz or higher). Vascular centers have
been provided with a medical DICOM recorder (MDR) in
order to transfer carotid B-Mode ultrasound images in a
uniform DICOM format to the centralized imaging core
laboratory (Bioclinica). The image depth will be standard-
ized at 4 cm or close to that, with a single focus zone and
no zoom, a high frame rate, low persistence, and optimized
image gain settings. The region of interest in the CCA will
be imaged at baseline at an angle that displays the clearest
near and far wall boundaries (optimal angle) and at three
predetermined angles of 30° increments according to the
Meijer carotid arc. The optimal angle at baseline is noted,
and will be consulted on subsequent visits. A quality
control procedure regarding image quality, protocol com-
pliance, and completeness of study data is being performed
for each vascular examination.
Ultrasonographic analysis
For the measurement of CIMT, the region of interest (ROI)
is defined as the CCA segment at least 10 mm below the
bifurcation (Fig. 2). CIMT will be assessed in longitudinal
view on the far wall of right and left CCA on a 10-mm
length in a region free of plaque. For assessment of plaque,
longitudinal and transversal images will be recorded in the
right and left carotid trees (CCA, bifurcation, and ICA)
from the origin of the cervical CCA to the first 30 mm of
the ICA. Image analysis will be performed using the
Arterial Measurement System II and automated contour
detection after positioning a measurement box (10 mm
wide) will be verified and manually corrected if needed
[22]. CIMT assessment will be performed by batch reading
after completion of all vascular examinations for each
patient.
If a plaque is present, ultrasound images will be
recorded, as well as will information on the number of
plaques present and their location. A plaque is defined as a
focal structure that encroaches into the arterial lumen of at
least 0.5 mm or 50% of the surrounding CIMT value or
demonstrates a thickness of ≥1.5 mm as measured from the
media-adventitia interface to the intima-lumen interface
[16]. For qualitative assessment, plaques will be graded as
follows: (1) none (complete absence, CIMT thickening may
be observed); (2) minimal (small isolated thickening); (3)
moderate (visible plaque, causing a modest degree diameter














>48 h, = 3 months
TIA = 8 days
Fig. 1 The PERFORM Vascu-
lar Project: Study design.
TIA, transient ischemic attack.
*Prior to first study drug intake
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diameter); or (5) occlusion [17, 23].
Carotid stiffness will be assessed, as previously
described, using ultrasound and blood pressure [24].
Stroke changes in carotid diameter will be calculated from
the 5-second video clip acquired at the optimal angle from
automated boundary tracing during at least three cardiac
cycles. Brachial blood pressure recordings made after
completion of the left and right carotid CIMT measure-
ments will be used. Central pulse pressure will be
calibrated from the diameter-time curve and brachial
blood pressure [25]. Distensibility is defined as the ratio
of relative stroke change in diameter on pulse pressure.
Carotid stiffness is expressed as the inverse of the square
root of distensibility, to give similar information to aortic
stiffness [26].
All ultrasound images will be evaluated and analyzed
centrally by an independent imaging core laboratory
(Bioclinica, Leiden, The Netherlands, BI). The core
laboratory will perform a centralized quality control for
ultrasound acquisition, notably for image quality and
protocol deviations, and variability. Assessment of local
arterial stiffness will be evaluated and analyzed centrally at
the Hôpital Georges Pompidou Core Centre (HEGP Paris,
France), from ultrasound images provided by Bioclinica.
Cineloops will be analyzed by Bioclinica and diameter
values will be extracted along time. Time series will be sent
to HEGP and analyzed with dedicated software.
Quality control and reproducibility
The quality control process included a uniform training
program for the sonographers and variability studies for
the central readers. An initial reader variability study has
been performed for two readers on a random selection of
58 independent images from baseline and M12 scans. The
inter-reader Intraclass correlation coefficient for the mean
common CIMT was 0.94 (95% confidence interval [CI]:
[0.872; 0.963]). Intra-reader intraclass correlation coeffi-
cients for the mean common CIMT were 0.93 for reader 1
(95% CI: [0.893; 0.961]) and 0.92 for reader 2 (95% CI:
[0.875; 0.954]). Two additional variability assessments
will be performed, one before the beginning of the batch
reading to certify the central readers, and another during
the batch reading. Should the reader intraclass correlation
coefficient be less than 0.80, a new training session will be
held, and the reader will complete a new assessment of
reproducibility.
As regards plaque reporting, studies of reproducibility
between the core laboratory and the sonographers have
been carried out. Plaque score and count in 47 subjects with
an available M0 and M12 scan were analyzed by the core
laboratory and compared with the sonographers’ reports.
The increase in the plaque count was evaluated at +14% by
the core laboratory between M12 and M0 compared with
+13% by the sonographers. Similar results were found in a
second study among 38 patients with M0, M12, and M24
available timepoints. These findings comply with those
reported by other groups [23].
Endpoints
The primary endpoint of the PERFORM Vascular Project is
the annualized rate of change in the mean common CIMT
(mm per year), on the basis of the assessments made at
baseline (M0), M12, M24, M36 (if applicable) and/or at the
final visit. The secondary endpoints are the change in mean
common CIMT from baseline (M0) to final visit (mm), the
number of emergent carotid plaques in both carotid systems
(left and right) and the change in carotid stiffness from
baseline to final visits.
Baseline characteristics
Recruitment into the PERFORM Vascular Project started in
February 2006 and the last patient was randomized in
March 2008. A total of 1,141 patients were randomized
from 52 vascular centers in 16 countries; 37% of the
population were recruited in Western Europe, 58% in
Eastern Europe, 3% in Australia, and 2% in Canada.
Demographic characteristics and past medical history are
presented in Table 1.
The mean age of the population was 66.2±6.5 years
(range 54–80 years), with 12% of patients over 75 years.







Fig. 2 Carotid tree: region of interest. Left: internal and external carotid
arteries; Middle: carotid bifurcation; Right: common carotid artery
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lesterolemia (54%), and diabetes (29%). Twelve percent of
the population reported a previous ischemic stroke and 8%
a previous TIA, while 8% had a history of myocardial
infarction. These data are largely comparable to the main
study population characteristics [4], except for the geo-
graphic distribution of the recruitment, which resulted in a
higher proportion of patients of Caucasian origin in the
Vascular Project (99% versus 83% in the main study) and a
higher proportion of patients with hypercholesterolemia
(54% versus 48% in the main study). This is most likely
due to the inclusion criteria of patients in the Vascular
Project, which require patients with at least one carotid
plaque at the baseline examination. In addition, the
Vascular Project population is slightly more likely to be
receiving angiotensin-converting enzyme inhibitor than the
main study population (63% versus 55%).
Data analytic approach
The PERFORM Vascular Project results will be analyzed by
the Robertson Centre for Biostatistics, University of Glas-
gow, UK, and subsequently validated by the Biometry
Division of the Institut de Recherches Internationales Servier.
The expected mean follow-up is 36 months. Assuming an
expected standard deviation of 0.11 mm of the rate of change
in common CIMT and a treatment withdrawal rate of 10%
per year, we estimate that 1,100 patients are necessary to
detect a treatment-related CIMT change of 0.025 mm (i.e.,
0.01 mm/year) for a statistical power of at least 90% using a
two-sided test with a 5% type 1 error rate.
The analyses will be performed in all patients in the full
analysis set and in the per protocol set, i.e. patients from the
full analysis set who are compliant with the protocol. The
type 1 error will be set at 5% (two-sided) for all statistical
tests and 95% CIs will be provided.
The effect of terutroban versus aspirin on the primary
endpoint (rate of change of common CIMT) will be
analyzed using a linear mixed-effects model adjusted for
baseline value. Comparison of the treatment groups for the
secondary endpoints of mean common CIMT and carotid
stiffness will be performed in a similar manner using a
general linear model with baseline value as a covariate. The
number of emergent carotid plaques will be compared for
the two groups by Poisson regression.
Organization
The organization of the main PERFORM study has been
described at length elsewhere [3]. The PERFORM Vascular
Project is supervised by the Vascular Scientific Committee,
comprising five members: Prof M.G. Hennerici (Chairman),
Prof I. Ford, Prof M.L. Bots, Prof S. Laurent, and Prof P.J.
Touboul. Independent centralized reading of the ultrasound
images is performed by Bioclinica, Leiden, The Netherlands.
The investigators of the PERFORM Vascular Project are
listed at the end of this article.
Conclusion
The PERFORM Vascular Project is part of the largest
ongoing trial in secondary prevention of stroke and will
study prospectively the effect of terutroban as compared to
aspirin on the progression of the CIMT in a large number of
patients.
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Mean age, years, mean±SD 66.2±6.5
Age, %
<65 years 44















Prior history of cerebral infarction 12
Angina pectoris 10
Hypertriglyceridemia 12
Prior history of TIA 8
Myocardial infarction 8




Angiotensin-converting enzyme inhibitors 63
aRecorded between index stroke and randomization
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